
    
      This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed
      to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well
      characterized PCOS. \

      The study will be conducted over a period of up to 34 weeks and will include Screening (Days
      -28 to -7) Phase, a 24-week Treatment Phase following randomization on Day 1.

      The primary endpoint of the study is change in hepatic fat content from baseline following 24
      weeks of treatment as measured by MRI-PDFF.
    
  